Colin J. Meyer

6.7k total citations · 2 hit papers
82 papers, 5.2k citations indexed

About

Colin J. Meyer is a scholar working on Molecular Biology, Biochemistry and Nephrology. According to data from OpenAlex, Colin J. Meyer has authored 82 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Molecular Biology, 12 papers in Biochemistry and 10 papers in Nephrology. Recurrent topics in Colin J. Meyer's work include Genomics, phytochemicals, and oxidative stress (32 papers), Mitochondrial Function and Pathology (9 papers) and Genetic Neurodegenerative Diseases (6 papers). Colin J. Meyer is often cited by papers focused on Genomics, phytochemicals, and oxidative stress (32 papers), Mitochondrial Function and Pathology (9 papers) and Genetic Neurodegenerative Diseases (6 papers). Colin J. Meyer collaborates with scholars based in United States, Australia and United Kingdom. Colin J. Meyer's co-authors include Melissa Krauth, Melanie Chin, Janet Wittes, Pablo E. Pérgola, Robert D. Toto, Paul Audhya, Heidi Christ‐Schmidt, Glenn M. Chertow, Stacey Ruiz and Angie Goldsberry and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Circulation.

In The Last Decade

Colin J. Meyer

80 papers receiving 5.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

2013 784 citations Paul Audhya, Melanie Chin et al. New England Journal of Medicine profile →
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

2011 707 citations Pablo E. Pérgola, Philip Raskin et al. New England Journal of Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Colin J. Meyer	3.2k	952	580	562	436	82	5.2k
Zhanjun Jia	2.0k 0.6×	1.0k 1.1×	432 0.7×	367 0.7×	321 0.7×	174	4.3k
Songming Huang	1.9k 0.6×	1.2k 1.3×	419 0.7×	357 0.6×	345 0.8×	183	4.3k
Ming‐Zhi Zhang	1.5k 0.5×	855 0.9×	433 0.7×	647 1.2×	487 1.1×	83	4.1k
I. George Fantus	2.2k 0.7×	549 0.6×	489 0.8×	925 1.6×	903 2.1×	66	4.5k
Toshiro Sugimoto	2.1k 0.7×	1.5k 1.5×	413 0.7×	907 1.6×	843 1.9×	100	5.3k
Diego Rodrı́guez-Puyol	1.5k 0.5×	1.3k 1.4×	503 0.9×	305 0.5×	1.0k 2.4×	172	4.6k
Radko Komers	1.2k 0.4×	1.2k 1.3×	210 0.4×	666 1.2×	689 1.6×	102	3.6k
Keizo Kanasaki	2.4k 0.8×	1.2k 1.2×	645 1.1×	1.3k 2.3×	829 1.9×	143	6.6k
Jay C. Jha	902 0.3×	599 0.6×	460 0.8×	453 0.8×	519 1.2×	38	2.5k
Prabal K. Chatterjee	1.4k 0.5×	890 0.9×	395 0.7×	197 0.4×	760 1.7×	67	3.8k

Countries citing papers authored by Colin J. Meyer

Since Specialization

Citations

This map shows the geographic impact of Colin J. Meyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colin J. Meyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colin J. Meyer more than expected).

Fields of papers citing papers by Colin J. Meyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colin J. Meyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colin J. Meyer. The network helps show where Colin J. Meyer may publish in the future.

Co-authorship network of co-authors of Colin J. Meyer

This figure shows the co-authorship network connecting the top 25 collaborators of Colin J. Meyer. A scholar is included among the top collaborators of Colin J. Meyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colin J. Meyer. Colin J. Meyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lynch, David R., Angie Goldsberry, Christian Rummey, et al.. (2023). Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data. Annals of Clinical and Translational Neurology. 11(1). 4–16. 24 indexed citations

Lynch, David R., Melanie Chin, Sylvia Boesch, et al.. (2022). Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed‐Start Analysis of the MOXIe Extension. Movement Disorders. 38(2). 313–320. 55 indexed citations

Lynch, David R., Melanie Chin, Martin B. Delatycki, et al.. (2020). Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study). Annals of Neurology. 89(2). 212–225. 177 indexed citations

Hodi, F. Stephen, Dmitry I. Gabrilovich, Melanie Chin, et al.. (2017). A phase 1b/2 study of omaveloxolone in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma. Annals of Oncology. 28. xi30–xi30. 5 indexed citations

Bubb, Kristen J., Cindy Kok, Owen Tang, et al.. (2016). Abstract 15540: NRF2 Upregulation Attenuates Post-Infarct Ventricular Remodeling by Modifying Redox Signalling. Circulation. 134. 1 indexed citations

Oudiz, Ronald J., Colin J. Meyer, Melanie Chin, et al.. (2015). Initial Data Report from “LARIAT”: A Phase 2 Study of Bardoxolone Methyl in PAH Patients on Stable Background Therapy. CHEST Journal. 148(4). 639A–639A. 17 indexed citations

Aminzadeh, Mohammad A., Scott A. Reisman, Nosratola D. Vaziri, et al.. (2013). The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease. Xenobiotica. 44(6). 570–578. 74 indexed citations

Hong, David S., Razelle Kurzrock, Jeffrey G. Supko, et al.. (2012). A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas. Clinical Cancer Research. 18(12). 3396–3406. 197 indexed citations

Xing, Yifan, Ting Niu, Wenjuan Wang, et al.. (2012). Triterpenoid Dihydro-CDDO-Trifluoroethyl Amide Protects against Maladaptive Cardiac Remodeling and Dysfunction in Mice: A Critical Role of Nrf2. PLoS ONE. 7(9). e44899–e44899. 55 indexed citations

10.

Wu, Qing, Yanxia Wang, Colin J. Meyer, et al.. (2011). Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1. American Journal of Physiology-Renal Physiology. 300(5). F1180–F1192. 136 indexed citations

11.

Pérgola, Pablo E., Melissa Krauth, Jesse W. Huff, et al.. (2011). Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD. American Journal of Nephrology. 33(5). 469–476. 197 indexed citations

12.

Pérgola, Pablo E., Philip Raskin, Robert D. Toto, et al.. (2011). Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes. New England Journal of Medicine. 365(4). 327–336. 707 indexed citations breakdown →

13.

Nagaraj, Srinivas, Je-In Youn, Hannah Weber, et al.. (2010). Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer. Clinical Cancer Research. 16(6). 1812–1823. 225 indexed citations

14.

Tsao, Twee, Steven M. Kornblau, Stephen Safe, et al.. (2010). Role of Peroxisome Proliferator-Activated Receptor-γ and Its Coactivator DRIP205 in Cellular Responses to CDDO (RTA-401) in Acute Myelogenous Leukemia. Cancer Research. 70(12). 4949–4960. 39 indexed citations

15.

Auletta, Jeffery J., et al.. (2010). The Synthetic Triterpenoid, CDDO-Me, Modulates the Proinflammatory Response to In Vivo Lipopolysaccharide Challenge. Journal of Interferon & Cytokine Research. 30(7). 497–508. 27 indexed citations

16.

Ichikawa, Tomonaga, Jinqing Li, Colin J. Meyer, et al.. (2009). Dihydro-CDDO-Trifluoroethyl Amide (dh404), a Novel Nrf2 Activator, Suppresses Oxidative Stress in Cardiomyocytes. PLoS ONE. 4(12). e8391–e8391. 93 indexed citations

17.

Hyer, Marc L., Ranxin Shi, Maryla Krajewska, et al.. (2008). Apoptotic Activity and Mechanism of 2-Cyano-3,12-Dioxoolean-1,9-Dien-28-Oic-Acid and Related Synthetic Triterpenoids in Prostate Cancer. Cancer Research. 68(8). 2927–2933. 52 indexed citations

18.

Hong, David S., Razelle Kurzrock, Jeffrey G. Supko, et al.. (2007). Phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies. Molecular Cancer Therapeutics. 6. 4 indexed citations

19.

Conrad, Charles A., et al.. (2007). Phase I clinical pharmacokinetics of RTA 744 (berubicin(B)), a blood-brain barrier penetrating anthracycline active against high grade glioma, and evaluation of its 13-hydroxy metabolite, berubicinol (B-ol). Molecular Cancer Therapeutics. 6. 2 indexed citations

20.

Kosakowska‐Cholody, Teresa, et al.. (2007). Gene expression profiles in HCT116 and HT29 cells exposed to RTA 502 lead to insights into the mechanism of action. Cancer Research. 67. 4895–4895. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact